Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Luminex LMNX -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (6)	4/1/2002 7:14:57 PM
From: mopgcw	Read Replies (1) \| Respond to of 11

Luminex Puts 1Q Below Earlier Guidance DOW JONES NEWSWIRES AUSTIN, Texas -- Luminex Corp. (LMNX) expects that first-quarter financial results will be "significantly" below its prior guidance due to continued delays in the commercialization timetables of its customers. Based on preliminary results, the maker of biological testing technologies expects a wider-than-expected first-quarter loss of 20 cents to 23 cents a share on revenue of $2.2 million to $2.7 million. In a press release Monday, Luminex said its revenue continues to be hurt by the lengthy and unpredictable sales cycle for its instruments and consumable products. A Thomson Financial/First Call survey of seven analysts produced a mean loss estimate of 17 cents a share, while two analysts surveyed produced a consensus revenue estimate of $4.55 million. The company's shares were halted for news at $11.44 on the Nasdaq National Market.